• Chinese
Cover Image

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Abstract

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct's new report, "Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018" provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD) million data for each segment and sub-segment within seven market categories - Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct's team of industry experts.

Scope

  • Market size and company share data for In Vitro Diagnostics market categories - Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing.
  • Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the twelve market categories.
  • Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnostics market.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 10

2.1 What is This Report About? 10

3 In Vitro Diagnostics In Greece 11

3.1 In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 11

3.2 In Vitro Diagnostics, Greece, Company Share (2010-2011) 17

4 Clinical Chemistry In Greece 19

4.1 Clinical Chemistry Overall Revenue, (2004-2018) 19

4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 23

4.1.2 Urine Analysis, Revenue (2004-2018) 27

4.2 Clinical Chemistry Distribution Share (2010-2011) 31

4.3 Clinical Chemistry, Greece, Company Share (2010-2011) 32

5 Genetic Testing In Greece 34

5.1 Genetic Testing Overall Revenue, (2004-2018) 34

5.2 Genetic Testing Distribution Share (2010-2011) 38

5.3 Genetic Testing, Greece, Company Share (2010-2011) 39

6 Haematology In Greece 41

6.1 Haematology Overall Revenue, (2004-2018) 41

6.1.1 Haematology Reagents, Revenue, (2004-2018) 45

6.1.2 Immunohaematology, Revenue (2004-2018) 49

6.1.3 Haemostasis, Revenue (2004-2018) 53

6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 57

6.2 Haematology Distribution Share (2010-2011) 61

6.3 Haematology, Greece, Company Share (2010-2011) 62

7 Histology And Cytology In Greece 64

7.1 Histology And Cytology Overall Revenue, (2004-2018) 64

7.2 Histology And Cytology Distribution Share (2010-2011) 68

7.3 Histology And Cytology, Greece, Company Share (2010-2011) 69

8 Immuno Chemistry In Greece 71

8.1 Immuno Chemistry Overall Revenue, (2004-2018) 71

8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 75

8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 79

8.1.3 Endocrinology Tests, Revenue (2004-2018) 83

8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 87

8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 91

8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 95

8.2 Immuno Chemistry Distribution Share (2010-2011) 99

8.3 Immuno Chemistry, Greece, Company Share (2010-2011) 100

9 Infectious Immunology In Greece 102

9.1 Infectious Immunology Overall Revenue, (2004-2018) 102

9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 106

9.2 Infectious Immunology Distribution Share (2010-2011) 110

9.3 Infectious Immunology, Greece, Company Share (2010-2011) 111

10 Microbiology Culture In Greece 113

10.1 Microbiology Culture Overall Revenue, (2004-2018) 113

10.1.1 Microbiology Analyzers, Revenue (2004-2018) 117

10.2 Microbiology Culture Distribution Share (2010-2011) 121

10.3 Microbiology Culture, Greece, Company Share (2010-2011) 122

11 Overview of Key Companies in Greece In Vitro Diagnostics Market 124

11.1 F. Hoffmann-La Roche Ltd. 124

11.1.1 Company Overview 124

11.2 Siemens Healthcare 124

11.2.1 Company Overview 124

11.3 Abbott Laboratories 125

11.3.1 Company Overview 125

11.4 Beckman Coulter, Inc. 125

11.4.1 Company Overview 125

11.5 Ortho-Clinical Diagnostics Inc. 126

11.5.1 Company Overview 126

11.6 bioMerieux S.A. 126

11.6.1 Company Overview 126

11.7 Sysmex Corporation 127

11.7.1 Company Overview 127

11.8 Becton, Dickinson and Company 127

11.8.1 Company Overview 127

11.9 Bio-Rad Laboratories, Inc. 128

11.9.1 Company Overview 128

11.10 DiaSorin S.p.A 128

11.10.1 Company Overview 128

11.11 Qiagen N.V. 129

11.11.1 Company Overview 129

11.12 Diagnostica Stago, Inc. 129

11.12.1 Company Overview 129

11.13 Thermo Fisher Scientific Inc. 130

11.13.1 Company Overview 130

11.14 Horiba, Ltd. 130

11.14.1 Company Overview 130

11.15 Gen-Probe Incorporated 131

11.15.1 Company Overview 131

11.16 Grifols, S.A. 131

11.16.1 Company Overview 131

11.17 Life Technologies Corporation 132

11.17.1 Company Overview 132

11.18 Immucor, Inc. 132

11.18.1 Company Overview 132

11.19 Cellestis Limited 133

11.19.1 Company Overview 133

11.20 Danaher Corporation 133

11.20.1 Company Overview 133

11.21 Phadia AB 134

11.21.1 Company Overview 134

12 Appendix 135

12.1 Global Markets Direct Research Methodology 135

12.2 Definitions of Markets Covered in the Report 136

12.2.1 In Vitro Diagnostics 136

12.3 Secondary Research 147

12.4 Primary Research 147

12.5 Models 148

12.6 Forecasts 148

12.7 Expert Panel Validation 148

12.8 Currency Conversion 149

12.9 Contact Us 149

12.10 Disclaimer 149

List of Tables

1.1 List of Tables

Table 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 12

Table 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011 14

Table 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 16

Table 4: In Vitro Diagnostics, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 18

Table 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 20

Table 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 22

Table 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 24

Table 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 26

Table 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 28

Table 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 30

Table 11: Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 31

Table 12: Clinical Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 33

Table 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 35

Table 14: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 37

Table 15: Genetic Testing, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 38

Table 16: Genetic Testing, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 40

Table 17: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 42

Table 18: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 44

Table 19: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 46

Table 20: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 48

Table 21: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 50

Table 22: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 52

Table 23: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 54

Table 24: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 56

Table 25: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 58

Table 26: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 60

Table 27: Haematology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61

Table 28: Haematology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 63

Table 29: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 65

Table 30: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 67

Table 31: Histology And Cytology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 68

Table 32: Histology And Cytology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 70

Table 33: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 72

Table 34: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 74

Table 35: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 76

Table 36: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 78

Table 37: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80

Table 38: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82

Table 39: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 84

Table 40: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 86

Table 41: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 88

Table 42: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 90

Table 43: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 92

Table 44: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 94

Table 45: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 96

Table 46: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 98

Table 47: Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 99

Table 48: Immuno Chemistry, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 101

Table 49: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 103

Table 50: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 105

Table 51: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 107

Table 52: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 109

Table 53: Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 110

Table 54: Infectious Immunology, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 112

Table 55: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 114

Table 56: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 116

Table 57: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 118

Table 58: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 120

Table 59: Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD Constant, 2010-2011 121

Table 60: Microbiology Culture, Greece, Company Share by Revenue ($m), USD Constant, 2010-2011 123

List of Figures

1.2 List of Figures

Figure 1: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, 2004-2018 11

Figure 2: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Historic, 2004-2011 13

Figure 3: In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 15

Figure 4: In Vitro Diagnostics, Greece, Company Share (%), 2011 17

Figure 5: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 19

Figure 6: Clinical Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 21

Figure 7: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 23

Figure 8: Clinical Chemisty Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 25

Figure 9: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 27

Figure 10: Urine Analysis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 29

Figure 11: Clinical Chemistry, Greece, Company Share (%), 2011 32

Figure 12: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 34

Figure 13: Genetic Testing, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 36

Figure 14: Genetic Testing, Greece, Company Share (%), 2011 39

Figure 15: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 41

Figure 16: Haematology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 43

Figure 17: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 45

Figure 18: Haematology Reagents, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 47

Figure 19: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 49

Figure 20: Immunohaematology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 51

Figure 21: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 53

Figure 22: Haemostasis, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 55

Figure 23: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 57

Figure 24: Haematology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 59

Figure 25: Haematology, Greece, Company Share (%), 2011 62

Figure 26: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 64

Figure 27: Histology And Cytology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 66

Figure 28: Histology And Cytology, Greece, Company Share (%), 2011 69

Figure 29: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 71

Figure 30: Immuno Chemistry, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 73

Figure 31: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 75

Figure 32: Disease Specific Immunochemistry, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 77

Figure 33: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 79

Figure 34: Drugs of Abuse / Toxicology, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 81

Figure 35: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 83

Figure 36: Endocrinology Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 85

Figure 37: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 87

Figure 38: Immunochemistry Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 89

Figure 39: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 91

Figure 40: Therapeutic Drug Monitoring, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 93

Figure 41: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 95

Figure 42: Immunochemistry Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 97

Figure 43: Immuno Chemistry, Greece, Company Share (%), 2011 100

Figure 44: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 102

Figure 45: Infectious Immunology, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 104

Figure 46: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 106

Figure 47: Infectious Immunology Rapid Tests, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 108

Figure 48: Infectious Immunology, Greece, Company Share (%), 2011 111

Figure 49: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 113

Figure 50: Microbiology Culture, Greece, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 115

Figure 51: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 117

Figure 52: Microbiology Analyzers, Greece, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 119

Figure 53: Microbiology Culture, Greece, Company Share (%), 2011 122

Figure 54: Global Markets Direct Methodology 135

Show More
Pricing